Swine flu pandemic vaccine

Global H1N1 Vaccines Markets Report 2021: Market Reached a Value of $1.8 Billion in 2020 - Forecast to 2026

Retrieved on: 
Friday, April 23, 2021
Medical specialties, Influenza vaccines, Vaccination, Virology, Clinical medicine, Swine flu pandemic vaccine, Influenza A virus subtype H1N1, Vaccine, Vaccines, Medicine, Influenza vaccine, Swine flu pandemic

b'DUBLIN, April 23, 2021 /PRNewswire/ -- The "H1N1 Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global H1N1 vaccines market reached a value of US$ 1.8 Billion in 2020.

Key Points: 
  • b'DUBLIN, April 23, 2021 /PRNewswire/ -- The "H1N1 Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global H1N1 vaccines market reached a value of US$ 1.8 Billion in 2020.
  • Looking forward, the global H1N1 vaccines market to exhibit moderate growth during the next five years.\nThe H1N1 virus is an infectious disease characterized by a persistent cough, high fever, red-watery eyes, body aches and headache.
  • The illness is known to have a detrimental effect on the existing chronic ailments, such as Pneumonia, Chronic Obstructive Pulmonary Disease (COPD) and Bronchitis, and can be fatal in severe cases.
  • H1N1 vaccines are a preventive measure administered through intradermal and intranasal procedures to provide active immunization against the virus.\nIncreasing incidences of epidemic H1N1 infection and declining immunity of the general population are among the key factors driving the market growth.

Global H1N1 Vaccines Markets, Opportunity and Forecast Report 2021-2026: Analysis of Key Brands - Agripal, Fiuarix, Influgen, Influvac, Nasovac, & Vaxigrip - ResearchAndMarkets.com

Retrieved on: 
Monday, April 19, 2021
Infectious diseases, Pharmaceutical, Health, Respiratory diseases, Medical specialties, Vaccination, Influenza vaccines, Swine flu pandemic vaccine, Influenza A virus subtype H1N1, Bronchitis, Haemophilus influenzae, Influenza vaccine, Swine flu pandemic

b'The "H1N1 Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global H1N1 vaccines market reached a value of US$ 1.8 Billion in 2020.

Key Points: 
  • b'The "H1N1 Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global H1N1 vaccines market reached a value of US$ 1.8 Billion in 2020.
  • Looking forward, the global H1N1 vaccines market to exhibit moderate growth during the next five years.\nThe H1N1 virus is an infectious disease characterized by a persistent cough, high fever, red-watery eyes, body aches and headache.
  • The illness is known to have a detrimental effect on the existing chronic ailments, such as Pneumonia, Chronic Obstructive Pulmonary Disease (COPD) and Bronchitis, and can be fatal in severe cases.
  • H1N1 vaccines are a preventive measure administered through intradermal and intranasal procedures to provide active immunization against the virus.\nIncreasing incidences of epidemic H1N1 infection and declining immunity of the general population are among the key factors driving the market growth.

National Research Institute’s Chief Medical Officer, Dr. Mark Leibowitz, Shares His Experience as Principal Investigator for COVID-19 Vaccine Trials

Retrieved on: 
Tuesday, February 16, 2021
Research, Infectious diseases, Clinical trials, Hispanic, Health, Consumer, Pharmaceutical, General Health, Science, Medical research, Medicine, Health sciences, Health, Clinical trials, COVID-19 vaccine, Vaccine, BioNTech, Swine flu pandemic vaccine

National Research Institute (NRI) has participated in the enrollment of multiple COVID-19 vaccine trials, two of which have been led by NRIs Chief Medical Officer, Mark Leibowitz, M.D.

Key Points: 
  • National Research Institute (NRI) has participated in the enrollment of multiple COVID-19 vaccine trials, two of which have been led by NRIs Chief Medical Officer, Mark Leibowitz, M.D.
  • As Principal Investigator for recent COVID-19 vaccine studies, Dr. Leibowitz answers frequently asked questions and shares his expert opinion on vaccine research, safety, and benefits.
  • What can you share about your experience as principal investigator for the COVID-19 vaccine trials?
  • National Research Institutes mission is to provide access to innovative therapies and to bring hope to our community through clinical research.

New Survey by National Foundation for Infectious Diseases Underscores Need to Build Trust in COVID-19 and Flu Vaccines Among Communities of Color

Retrieved on: 
Thursday, February 4, 2021
Vaccination, Medical specialties, Medicine, Health sciences, Vaccine, Virology, COVID-19 vaccine, Vaccines, Swine flu pandemic vaccine, Helen Petousis-Harris

The NFID survey found that only 49 percent of Black adults plan to get vaccinated against COVID-19.

Key Points: 
  • The NFID survey found that only 49 percent of Black adults plan to get vaccinated against COVID-19.
  • Among that group, only 19 percent plan to get vaccinated as soon as possible, while approximately 31 percent prefer to wait.
  • Less than a quarter of survey respondents said they were extremely or very confident in COVID-19 vaccine efficacy, safety, or adequate testing among US Black adults.
  • Top reasons cited were concerns about potential side effects and the misconception about getting flu from the vaccine.

1.7 million doses of COVID-19 vaccine needed to achieve herd immunity in Travis County, Texas

Retrieved on: 
Friday, January 29, 2021
Vaccination, Medical specialties, Health sciences, Medicine, Medical research, Epidemiology, Biotechnology, Vaccine, COVID-19 vaccine, Herd immunity, Swine flu pandemic vaccine, Vaccine hesitancy

Austin, Texas, Jan. 29, 2021 (GLOBE NEWSWIRE) -- About 1.7 million doses of COVID-19 vaccine will need to be administered for Travis County to reach a herd immunity level of 67 percent, according to research released by Sendero Health Plans.

Key Points: 
  • Austin, Texas, Jan. 29, 2021 (GLOBE NEWSWIRE) -- About 1.7 million doses of COVID-19 vaccine will need to be administered for Travis County to reach a herd immunity level of 67 percent, according to research released by Sendero Health Plans.
  • We estimate that to administer 1.7 million doses over the course of 26 weeks, 65,000 doses will need to be administered weekly.
  • To reach herd immunity in Travis County, 67 percent coverage is needed more than two times over what was achieved ten years ago.
  • Moreover, when compared to the H1N1 vaccination effort, 1 million more doses of the COVID-19 vaccine will need to be administered.

Global Influenza Vaccine Production and Distribution Market Report 2020:Impact of COVID-19, Vaccine Makeup, Vaccine Effectiveness, and Reimbursement

Retrieved on: 
Thursday, December 31, 2020
Medical specialties, Drugs, Vaccines, Influenza vaccines, Vaccination, Influenza, Influenza vaccine, Vaccine, Live attenuated influenza vaccine, Flu season, Swine flu pandemic vaccine, COVID-19 vaccine

DUBLIN, Dec. 31, 2020 /PRNewswire/ -- The "2020 Influenza Vaccine Production and Distribution Market Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 31, 2020 /PRNewswire/ -- The "2020 Influenza Vaccine Production and Distribution Market Report" report has been added to ResearchAndMarkets.com's offering.
  • The 2020-2021 flu season will be the first full influenza season coinciding with the COVID-19 pandemic, creating concerns of potential coinfections and overwhelmed hospitals.
  • The 2020 HIDA Influenza Vaccine Production & Distribution Market Report provides insights into the upcoming flu season including the impact of COVID-19, vaccine makeup, vaccine effectiveness, and reimbursement.
  • Insights include:
    52% of Americans received a vaccine last season; experts this year target a 70% vaccination rate
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

2020 Influenza Vaccine Production and Distribution Market Report - ResearchAndMarkets.com

Retrieved on: 
Monday, December 28, 2020
General Health, Pharmaceutical, Health, Medical specialties, Drugs, Vaccines, Influenza vaccines, Influenza vaccine, Vaccine, Influenza, Live attenuated influenza vaccine, Flu season, Vaccination, Swine flu pandemic vaccine, Global Advisory Committee on Vaccine Safety

The "2020 Influenza Vaccine Production and Distribution Market Report" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2020 Influenza Vaccine Production and Distribution Market Report" has been added to ResearchAndMarkets.com's offering.
  • The 2020-2021 flu season will be the first full influenza season coinciding with the COVID-19 pandemic, creating concerns of potential coinfections and overwhelmed hospitals.
  • The 2020 HIDA Influenza Vaccine Production & Distribution Market Report provides insights into the upcoming flu season including the impact of COVID-19, vaccine makeup, vaccine effectiveness, and reimbursement.
  • Insights include:
    52% of Americans received a vaccine last season; experts this year target a 70% vaccination rate
    View source version on businesswire.com: https://www.businesswire.com/news/home/20201228005101/en/

Guillain-Barré Experts Clarify COVID-19 Vaccine Confusion with Open Letter to Dr. A.S. Fauci

Retrieved on: 
Monday, December 21, 2020
Medical specialties, Medicine, Health, Vaccines, Influenza vaccines, Swine flu pandemic vaccine, Influenza vaccine, Swine influenza, Vaccine, COVID-19 vaccine, Influenza, Anthony Fauci

In response to a recent public statement made by Dr. A.S. Fauci, Director of NIAID, NIH, regarding the COVID-19 vaccine as it pertains to the GBS community, and to further clarify COVID-19 vaccine confusion among patients & caregivers, the following open letter to Dr. A.S.Fauci, has been authored as referenced.

Key Points: 
  • In response to a recent public statement made by Dr. A.S. Fauci, Director of NIAID, NIH, regarding the COVID-19 vaccine as it pertains to the GBS community, and to further clarify COVID-19 vaccine confusion among patients & caregivers, the following open letter to Dr. A.S.Fauci, has been authored as referenced.
  • "On the television show, you stated that people who had GBS in the past should avoid the COVID vaccines as they may cause another episode of GBS.
  • GBS was associated with the 1976/1977 swine flu vaccine at a rate of about 1 case/100,000 vaccinees.
  • In fact, the CDC recommends that everyone get the flu vaccine as the benefits of the vaccine outweigh the risks of GBS ( https://www.cdc.gov/vaccinesafety/concerns/guillain-barre-syndrome.html ).

Government of Canada Announces pan-Canadian Vaccine Injury Support Program

Retrieved on: 
Friday, December 11, 2020
Vaccination, Health, Drugs, Vaccines, Drug Safety, Vaccine adverse event, Vaccine, Public Health Agency of Canada, COVID-19 vaccine, Swine flu pandemic vaccine

Vaccines are only approved in Canada after thorough and independent review of the scientific evidence.

Key Points: 
  • Vaccines are only approved in Canada after thorough and independent review of the scientific evidence.
  • It is for this reason that the Public Health Agency of Canada (PHAC) isimplementing a pan-Canadian no-fault vaccine injury support program for all Health Canada approved vaccines, in collaboration with provinces and territories.
  • Once a vaccine is in use, Canada has a strong vaccine safety monitoring system that involves healthcare professionals, vaccine manufacturers, the provinces and territories, the Public Health Agency of Canada, and Health Canada, to alert public health authorities of changing trends or unusual adverse events that were not previously reported.
  • Over 20 countries around the world have national vaccine injury support programs, including all other G7 countries.

Children’s Hospital Los Angeles Offers FREE Flu Vaccination Family Clinic

Retrieved on: 
Friday, December 4, 2020
Pharmaceutical, General Health, Health, Children, Family, Infectious diseases, Hospitals, Consumer, Medical specialties, Health care, Clinical medicine, Vaccines, Influenza vaccine, Vaccine, Influenza, Swine flu pandemic vaccine, Swine flu pandemic

The American Academy of Pediatrics, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America recommends everyone over 6 months of age receive the flu vaccine every year.

Key Points: 
  • The American Academy of Pediatrics, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America recommends everyone over 6 months of age receive the flu vaccine every year.
  • With COVID-19 numbers still at dangerous levels, its now more crucial than every to be vigilant about your familys health.